LUNA18 is an orally bioavailable, cell-penetrant, macrocyclic peptide pan-RAS inhibitor (Chugai ’21Q3 earnings call) intended for the treatment of KRAS-mutant cancers. It disrupts the protein-protein interaction between KRAS and SOS, preventing RAS activation.
5 minute read
Sep. 26, 2023
A Clinical, Oral, Cell-Penetrant, Reversible, Macrocyclic Peptide Pan-RAS Inhibitor from mRNA Display
LUNA18
oral KRAS inhibitor Ph. I dose-escalation for metastatic solid tumors from mRNA display library hit J. Am. Chem. Soc., July 18, 2023 Chugai, Yokohama, JP
Author:
Loading...
